NTCOC
SRPT icon

Northern Trust Company of Connecticut’s Sarepta Therapeutics SRPT Stock Holding History

Northern Trust Company of Connecticut’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-18,960
Closed -$895K – 2029
2013
Q3 		$895K Buy
18,960
+4,770
+34% +$184K 0.01% 1380
2013
Q2 		$540K Buy
+14,190
New +$507K ﹤0.01% 1467

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Northern Trust Company of Connecticut's SRPT Position: Q4 2013 in Review

Northern Trust Company of Connecticut sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 18,960 shares — an estimated $895K sold.

Northern Trust Company of Connecticut first reported a position in SRPT in Q2 2013 and held it in 2 quarters. The position peaked at $895K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

  • Northern Trust Company of Connecticut reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Northern Trust Company of Connecticut sold 18,960 Sarepta Therapeutics shares in Q4 2013, an estimated $895K.
  • Northern Trust Company of Connecticut first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 2 quarters.
  • Northern Trust Company of Connecticut's Sarepta Therapeutics position peaked at $895K in Q3 2013.
  • 108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.